176 related articles for article (PubMed ID: 10942367)
1. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology.
Akin C; Schwartz LB; Kitoh T; Obayashi H; Worobec AS; Scott LM; Metcalfe DD
Blood; 2000 Aug; 96(4):1267-73. PubMed ID: 10942367
[TBL] [Abstract][Full Text] [Related]
2. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
3. Urinary 11β-PGF2α and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders.
Divekar R; Butterfield J
Allergy; 2015 Oct; 70(10):1230-8. PubMed ID: 26095439
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
[TBL] [Abstract][Full Text] [Related]
5. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis.
Lawrence JB; Friedman BS; Travis WD; Chinchilli VM; Metcalfe DD; Gralnick HR
Am J Med; 1991 Dec; 91(6):612-24. PubMed ID: 1750431
[TBL] [Abstract][Full Text] [Related]
6. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis.
Brockow K; Akin C; Huber M; Metcalfe DD
Clin Immunol; 2005 May; 115(2):216-23. PubMed ID: 15885646
[TBL] [Abstract][Full Text] [Related]
7. Slowly progressive systemic mastocytosis with high mast-cell burden and no evidence of a non-mast-cell hematologic disorder: an example of a smoldering case?
Akin C; Scott LM; Metcalfe DD
Leuk Res; 2001 Jul; 25(7):635-8. PubMed ID: 11377688
[TBL] [Abstract][Full Text] [Related]
8. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
9. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
[TBL] [Abstract][Full Text] [Related]
10. The faces of mast cell disease: bone marrow infiltrates in 3 patients with systemic mastocytosis.
Martinez AE; Medina AM; Hyde JA; Krill-Jackson E; Blaustein A; Schwartz M; Cabello-Inchausti B
Ann Diagn Pathol; 2005 Apr; 9(2):81-5. PubMed ID: 15806514
[TBL] [Abstract][Full Text] [Related]
11. Utility of paraffin section immunohistochemistry for C-KIT (CD117) in the differential diagnosis of systemic mast cell disease involving the bone marrow.
Natkunam Y; Rouse RV
Am J Surg Pathol; 2000 Jan; 24(1):81-91. PubMed ID: 10632491
[TBL] [Abstract][Full Text] [Related]
12. Treatment of three patients with systemic mastocytosis with interferon alpha-2b.
Worobec AS; Kirshenbaum AS; Schwartz LB; Metcalfe DD
Leuk Lymphoma; 1996 Aug; 22(5-6):501-8. PubMed ID: 8882964
[TBL] [Abstract][Full Text] [Related]
13. A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val.
Jordan JH; Fritsche-Polanz R; Sperr WR; Mitterbauer G; Födinger M; Schernthaner GH; Christian Bankl H; Gebhart W; Chott A; Lechner K; Valent P
Leuk Res; 2001 Jul; 25(7):627-34. PubMed ID: 11377687
[TBL] [Abstract][Full Text] [Related]
14. Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis.
Proelss J; Wenzel J; Ko Y; Bieber T; Bauer R
J Am Acad Dermatol; 2007 Mar; 56(3):453-7. PubMed ID: 17317486
[TBL] [Abstract][Full Text] [Related]
15. Transglutaminase 2 expressed in mast cells recruited into skin or bone marrow induces the development of pediatric mastocytosis.
Ahn YM; Hong GU; Kim SH; Lee HJ; Baek HS; Kim MN; Park KY; Ro JY
Pediatr Allergy Immunol; 2015 Aug; 26(5):438-45. PubMed ID: 25952500
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients.
Theoharides TC; Boucher W; Spear K
Int Arch Allergy Immunol; 2002 Aug; 128(4):344-50. PubMed ID: 12218373
[TBL] [Abstract][Full Text] [Related]
17. Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis.
Carter MC; Clayton ST; Komarow HD; Brittain EH; Scott LM; Cantave D; Gaskins DM; Maric I; Metcalfe DD
J Allergy Clin Immunol; 2015 Dec; 136(6):1673-1679.e3. PubMed ID: 26044856
[TBL] [Abstract][Full Text] [Related]
18. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis.
Escribano L; Díaz-Agustín B; Bellas C; Navalón R; Nuñez R; Sperr WR; Schernthaner GH; Valent P; Orfao A
Leuk Res; 2001 Jul; 25(7):563-70. PubMed ID: 11377681
[TBL] [Abstract][Full Text] [Related]
19. Mastocytosis: immunophenotypical features of the transformed mast cells are unique among hematopoietic cells.
Horny HP; Sotlar K; Valent P
Immunol Allergy Clin North Am; 2014 May; 34(2):315-21. PubMed ID: 24745676
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature.
Bernd HW; Sotlar K; Lorenzen J; Osieka R; Fabry U; Valent P; Horny HP
J Clin Pathol; 2004 Mar; 57(3):324-8. PubMed ID: 14990611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]